Literature DB >> 18421302

DNA damage-inducing agents elicit gamma-secretase activation mediated by oxidative stress.

S M Jin1, H J Cho, E S Jung, M-Y Shim, I Mook-Jung.   

Abstract

According to the amyloid cascade hypothesis, Alzheimer's disease is the consequence of neuronal cell death induced by beta-amyloid (Abeta), which accumulates by abnormal clearance or production. On the other hand, recent studies have shown cell death-induced alteration in amyloid precursor protein (APP) processing, suggesting potential mutual interactions between APP processing and cell death. We have shown previously that the cell death caused by DNA damage-inducing agents (DDIAs) facilitated gamma-secretase activity and Abeta generation in a Bax/Bcl-2-dependent, but caspase-independent manner. Here, we attempted to elucidate the downstream mechanism that modulates gamma-secretase activity in DDIA-treated cells. N-acetyl cysteine, a potent antioxidant, attenuated DDIA-induced enhancement of gamma-secretase activity but failed to rescue cell death. Overexpression of heat shock protein 70, which blocks cytochrome c release from mitochondria, also reduced gamma-secretase activity. Moreover, glutathione depletion significantly facilitated gamma-secretase activity and Abeta generation by enhancing the formation of higher molecular weight gamma-secretase complex before signs of cell death developed. Finally, Abeta treatment, a known inducer of oxidative stress, also increased gamma-secretase activity. Taken together, these results indicate that DDIA-induced gamma-secretase activation is dependent on augmented oxidative stress, and that Abeta and gamma-secretase may activate each other. On the basis of these results, we propose a feed-back loop between oxidative stress and Abeta generation mediated by gamma-secretase activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421302     DOI: 10.1038/cdd.2008.49

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  6 in total

1.  The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.

Authors:  C Kurz; I Ungerer; U Lipka; S Kirr; T Schütt; A Eckert; K Leuner; W E Müller
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

2.  L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1.

Authors:  Lin Cheng; Qiulian Wu; Zhi Huang; Olga A Guryanova; Qian Huang; Weinian Shou; Jeremy N Rich; Shideng Bao
Journal:  EMBO J       Date:  2011-02-04       Impact factor: 11.598

3.  UV irradiation accelerates amyloid precursor protein (APP) processing and disrupts APP axonal transport.

Authors:  Angels Almenar-Queralt; Tomas L Falzone; Zhouxin Shen; Concepcion Lillo; Rhiannon L Killian; Angela S Arreola; Emily D Niederst; Kheng S Ng; Sonia N Kim; Steven P Briggs; David S Williams; Lawrence S B Goldstein
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

4.  Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.

Authors:  H Song; J Hyun Boo; K Ho Kim; C Kim; Y-E Kim; J-H Ahn; G Sun Jeon; H Ryu; D E Kang; I Mook-Jung
Journal:  Cell Death Differ       Date:  2013-01-11       Impact factor: 15.828

5.  Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.

Authors:  Ravi P Sahu; Jesus A Ocana; Kathleen A Harrison; Matheus Ferracini; Christopher E Touloukian; Mohammed Al-Hassani; Louis Sun; Mathew Loesch; Robert C Murphy; Sandra K Althouse; Susan M Perkins; Paul J Speicher; Douglas S Tyler; Raymond L Konger; Jeffrey B Travers
Journal:  Cancer Res       Date:  2014-10-10       Impact factor: 12.701

6.  Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of Aβ-induced impaired axonal transport.

Authors:  Heesun Choi; Haeng Jun Kim; Jisoo Kim; Soohyun Kim; Jinhee Yang; Wonik Lee; Yeonju Park; Seung Jae Hyeon; Dong-Sup Lee; Hoon Ryu; Junho Chung; Inhee Mook-Jung
Journal:  Mol Neurodegener       Date:  2017-02-28       Impact factor: 14.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.